Durvalumab is a monoclonal human immunoglobulin G1 kappa (IgG1k) antibody that selectively inhibits the binding to PD-1 and CD801 of programmed cell death ligand-1 (PD-L1) (B7.1). The blockade of interactions between PD-L1/PD-1 and PD-L1/CD80 contributes to an improved immune response to antitumor and increased activation of T cells, enabling tumor cells to be destroyed by the T cells.
Use this medication precisely as recommended by your physician. Follow the prescription of your doctor carefully.
The medication dose given by your physician is based on your health conditions, other medications or food supplements taken, and your reaction to the treatment. To diminish risks for adverse effects, do not increase your dosage, thus take it regularly, or take it as instructed by your physician. Adverse events may still happen even at usual prescription dosages.
If your physician requests you to use this drug consistently, take it regularly to get the most benefits from it. To make you remember it better, take it at a fixed time every day.
Your doctor may need to modify your dosages to ease your symptoms or if you develop adverse reactions.